High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.

High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.
复制标题

DOI:
10.1038/srep35297
复制
发表时间:
2016-10-13
期刊:
影响因子:
4.6
通讯作者:
Nomura N
Nomura N
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Horita S;Nomura Y;Sato Y;Shimamura T;Iwata S;Nomura N

文献摘要

参考文献

被引文献

相似文献

Pembrolizumab是一种FDA批准的治疗性抗体,靶向程序性细胞死亡-1(PD-1),以阻断免疫检查点途径,用于治疗各种类型的癌症。它因其高度的功效而备受关注。最近,与人PD-1的细胞外结构域(PD-1 ECD)复合的派姆单抗(PemFab)的Fab片段的晶体结构被报道为分辨率为2.9 μ m。然而,这种相对低分辨率的结构数据未能提供关于结合界面处的界面水分子的充分信息,所述界面水分子基本上有助于治疗性抗体和靶标之间的亲和力和特异性。在这里,我们提出了独立确定的帕博利珠单抗(PemFv)的Fv片段与PD-1 ECD复合的晶体结构,分辨率为2.15 μ m。这种高分辨率结构允许精确映射相互作用,包括水介导的氢键,并首次提供了pembrolizumab对PD-1拮抗作用的连贯解释。我们的结构数据还为改进的抗PD-1疗法的合理设计提供了新的见解。
Pembrolizumab is an FDA-approved therapeutic antibody that targets the programmed cell death-1 (PD-1) to block the immune checkpoint pathway for the treatment of various types of cancer. It receives remarkable attention due to the high degree of efficacy. Very recently, the crystal structure of the Fab fragment of pembrolizumab (PemFab) in complex with the extracellular domain of human PD-1 (PD-1ECD) was reported at a resolution of 2.9 Å. However, this relatively low-resolution structural data fails to provide sufficient information on interfacial water molecules at the binding interface that substantially contribute to affinity and specificity between the therapeutic antibody and target. Here, we present the independently determined crystal structure of the Fv fragment of pembrolizumab (PemFv) in complex with the PD-1ECD at a resolution of 2.15 Å. This high-resolution structure allows the accurate mapping of the interaction including water-mediated hydrogen bonds and provides, for the first time, a coherent explanation of PD-1 antagonism by pembrolizumab. Our structural data also provides new insights into the rational design of improved anti-PD-1 therapeutics.
DOI: 10.1073/pnas.0406351101
发表时间: 2004-12-07
影响因子: 11.1
作者:
Thompson, RH;Gillettt, MD;Kwon, ED
通讯作者: Kwon, ED
DOI: 10.1107/s0907444909052925
发表时间: 2010-02
期刊: Acta crystallographica. Section D, Biological crystallography
影响因子: --
作者:
Adams PD;Afonine PV;Bunkóczi G;Chen VB;Davis IW;Echols N;Headd JJ;Hung LW;Kapral GJ;Grosse-Kunstleve RW;McCoy AJ;Moriarty NW;Oeffner R;Read RJ;Richardson DC;Richardson JS;Terwilliger TC;Zwart PH
通讯作者: Zwart PH
DOI: 10.1016/s1074-7613(00)80089-8
发表时间: 1999-08-01
期刊: IMMUNITY
影响因子: 32.4
作者:
Nishimura, H;Nose, M;Honjo, T
通讯作者: Honjo, T
DOI: 10.1073/pnas.0712278105
发表时间: 2008-02-26
影响因子: 11.1
作者:
Lin, David Yin-Wei;Tanaka, Yoshimasa;Garboczi, David N.
通讯作者: Garboczi, David N.
DOI: 10.1073/pnas.192461099
发表时间: 2002-09-17
影响因子: 11.1
作者:
Iwai, Y;Ishida, M;Minato, N
通讯作者: Minato, N